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Context: Multiple endocrine neoplasia type 1 (MEN1) disease is an autosomal dominant syndrome that
is believed to equally affect men and women. This assumption has never been confirmed.
Objective: The aims of this study were to evaluate the impact of gender on the prevalence of MEN1
lesions, on their lifetime probability of occurrence, and on the diagnosis of MEN1.
Design: Data regarding a study of 734 cases of MEN1 from the multicenter ‘Groupe d’e´tude des
Tumeurs Endocrines’ were analyzed.
Results: There were 57.8% females. The prevalence and probability of pancreatic tumors were higher
in males than in females (PZ0.06, PZ0.0004). This difference was due to gastrinomas. The
prevalence and probability of developing pituitary tumors were significantly greater in females
(P!0.001, P!0.0001). Thymic tumors were exclusively found in men. There were no significant
gender differences in the prevalence and the probability of developing hyperparathyroidism, or adrenal
and bronchial tumors, or in the proportion of positive genetic tests. A family history of MEN1 was more
frequently found in men than in women at the time of diagnosis (PZ0.02). In the case of pituitary
tumor, the proportion of patients diagnosed with MEN1 at the time of the first lesion was lower in
women (44.2%) than in men (67.3%).
Conclusion: The phenotype expression of the MEN1 disease gene was different in males and females.
In female patients, the possibility of MEN1 is not sufficiently taken into account. Any patient presenting
a lesion that belongs to the MEN1 spectrum, such as a pituitary tumor, should be closely questioned
about their family history and should be tested for hypercalcemia.
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Multiple endocrine neoplasia type 1 (MEN1) is an
inherited disease that predisposes carriers to primary
hyperparathyroidism (pHPT), endocrine enteropancrea-
tic tumors, pituitary tumors, and adrenal and thymic/
bronchial neuroendocrine tumors (th-NET/br-NET).ndocrinologyMEN1 disease may display various clinical associations,
and the criteria for diagnosis were established in Italy
(Gubbio) during an international MEN meeting and are
regularly updated (1–3). Most cases occur in the setting
of a family history of MEN1, but sporadic cases of MEN1
are encountered. MEN1 mutations are found in most
MEN1 patients but not in all. Indeed, up to 15% of indexDOI: 10.1530/EJE-10-0950
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mutation; this may be the result of alterations in
regulatory or UTRs of the MEN1 gene or possibly genes
other than MEN1 causing the disease (4). The MEN1
gene is an w10 kb gene located on chromosome
11q13, which encodes menin (5). MEN1 disease is
usually described as an autosomal dominant cancer
syndrome with very high penetrance and a similar
distribution in men and women (6). Nevertheless,
studies focusing on MEN1-related th-NET, largely
confined to men, show the importance of gender in at
least this type of lesion (7–10). There are large
variations between studies in the sex ratio, depending
on the center, the population size, and the type of lesion
studied. Several cohort studies that did not focus on
specific lesions suggested an overall female predomi-
nance of about 52–56% of MEN1 patients (11, 12).
In contrast, studies that focus on specific lesions
provided discordant sex ratios with a proportion of
females ranging, for example, from 36 to 58% in MEN1
patients with Zollinger–Ellison syndrome (ZES) (13–16).
Several years ago, the Groupe d’e´tude des Tumeurs
Endocrines (GTE) already pointed out the higher
prevalence of pituitary lesions in women than in men
(17). To our knowledge, no systematic evaluation of
gender differences in the phenotype expression of MEN1
disease has yet been conducted. This prompted us to
carry out a comprehensive analysis on this topic using a
large unselected population of 734 MEN1 patients from
the multicenter GTE network. These patients were
precisely defined in accordance with international
guidelines, were regularly followed up, and presented
either a familial background or were sporadic cases
(1–3, 18). Therefore, the inclusion of MEN1 patients in
the database was not dependent on a single center or
on a particular lesion-dependent aspect of the disease.
The aims of this study were to evaluate the impact of
gender on the prevalence of every MEN1 lesion, on their
lifetime probability of occurrence, and finally on the
time to the diagnosis of MEN1.Population and methods
The study population comprised of 734 MEN1 patients
presenting at least one MEN1 lesion and registered in
the GTE database. The GTE network for MEN1, created
in February 1991, includes clinical centers that are
scattered in the 22 regions of France and in Belgium
associated with the four genetics departments in charge
of the diagnosis. Data from MEN1 patients diagnosed
and regularly followed from 1956 to 1991 in the
clinical departments involved in the management of
MEN1 patients were incorporated into the GTE database
in 1991. Since 1991, GTE members have been required
to declare new cases for inclusion in the national MEN1
database. Moreover, the genetics departments regularly
detect new cases and family trees are established for allwww.eje-online.orgfamilial cases. They are also used to identify affected
family members.
To be included in the study, patients had to fulfill
specific diagnosis criteria in accordance with inter-
national guidelines (1–3): i) patients with a MEN1
mutation and presenting at least one of the following
symptomatic or silent lesions: pHPT, pancreatic, or
duodenal endocrine tumor; pituitary tumor; adrenal
tumor; th-NET; br-NET; and gastric enterochromaffin-
like tumor (ECLoma). ii) Patients belonging to a known
MEN1 family (at least one first-degree relative affected)
and presenting at least one of the aforementioned
lesions. iii) Patients without positive genetic testing or a
family background presenting at least two of the three
major MEN1 lesions (pHPT, pancreatic, or duodenal
endocrine tumor, pituitary tumor). This last category
includes 73 patients. They were considered with
caution and selected after a critical case-by-case
analysis following rules already published by the GTE
group (19). Criteria for the diagnosis of MEN1 lesions
have evolved over the study period since the first cases
were registered in the fifties. Before the parathormone
(PTH) dosage era, the diagnosis of pHPT was usually
based on clinical symptoms related to the presence of
urinary lithiasis associated to the presence of hypercal-
cemia with or without hypophosphatemia in relation
with a multiglandular disease or occurring in an
already known MEN1 family. Later on, pHPT was
defined as the association of hypercalcemia with
elevated or inappropriate PTH levels after ruling out
vitamin D insufficiency. ZES was diagnosed on a clinical
and/or pathological basis (gastrinoma) before the
introduction of biological criteria. Biological criteria
used for the diagnosis of ZES were based on the
measurement of gastrin concentration and gastric acid
secretion without and with dynamic secretory tests
(secretin) (20). Recently, additional criteria also tend to
be used when concomitant proton pomp inhibitors
(PPI) cannot be interrupted. A serum gastrin concen-
tration O1000 pg/ml in the presence of acidic gastric
juice (pH!2) confirms a diagnosis of ZES. Confirmed
diagnosis of insulinoma was based on the association of
fasting hypoglycemia associated with inappropriate
secretion of insulin, C-peptide, or pro-insulin (21). The
diagnosis of glucagonoma, VIPoma, or somatostati-
noma was based on specific clinical symptoms and/or a
peptide level repeatedly exceeding twice the upper limit
of the normal range (22). The diagnosis of non-
secreting pancreatic tumor (NSPT), pituitary tumor,
adrenal tumor, th-NET, and br-NET has evolved over
time since computed tomography (CT) became largely
available in the 1980s, endoscopic ultrasound (EUS)
and magnetic resonance imaging (MRI) in the 1990s.
Moreover, the diagnosis performance of these imaging
tools has improved steadily.
The ‘first lesion’ was defined as the lesion that was
discovered first, whatever the other possible MEN1-
associated lesions discovered during the following days
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feature was the age at the time of diagnosis for this
feature. A patient was considered to have a family
history of MEN1 when another MEN1 case was
discovered or highly suspected in the same family during
the pre-diagnosis period. Genetic analysis of the MEN1
sequence was performed in 583 cases (23). Families
with a common ancestor were considered a single family,
and all known affected members of each family were
included. The mutations were recorded in the database.
The study was approved by the ethics committee of Lyon
University Hospital, and genetic studies were performed
after informed consent had been provided by each
patient, according to French and Belgian laws.
The referent physician provided initial data for the
patient. A copy of each patient’s file was obtained and
stored in the Department of Epidemiology of Burgundy
School of Medicine. A computerized recording file (CRF)Table 1 Prevalence of MEN1 characteristics in males and females.
Males Females
Characteristics of MEN1 n (%) n (%) P*
Number of patients 310 (42.2) 424 (57.8)
Prevalence of lesions
Hyperparathyroidism 287 (92.6) 394 (92.9) 0.859
Duodeno-pancreatic tumors 189 (61.0) 229 (54.0) 0.060
ZES/gastrinomas 113 (36.5) 103 (24.3) !0.001
NSPT 43 (13.9) 70 (16.5) 0.328
Insulinomas 28 (9.0) 51 (12.0) 0.196
GVS 13 (4.2) 12 (2.8) 0.314
Pituitary tumors 94 (30.3) 197 (46.5) !0.001
Prolactinomas 47 (15.2) 108 (25.5) 0.001
Other adenomas 47 (15.2) 89 (21.0) 0.045
Adrenal tumors 59 (19.0) 76 (17.9) 0.702
Bronchial tumors 10 (3.2) 13 (3.1) 0.902
Thymic tumors 19 (6.1) 0 (0.0) !0.001
First lesion diagnoseda
Hyperparathyroidism 70.0 63.0 0.047
Duodeno-pancreatic tumors 39.0 27.4 0.001
Pituitary tumors 17.7 30.4 !0.001
Adrenal tumors 4.8 4.3 0.702
Bronchial tumors 0.7 1.4 0.321
Thymic tumors 1.6 0.0 0.009
Number of lesions at MEN1
diagnosis
0.806
One 136 (43.9) 177 (41.8)
Two 132 (42.6) 184 (43.4)
Three and more 42 (13.6) 63 (14.9)
Family history 0.023
Yes 249 (80.3) 307 (72.4)
No 58 (18.7) 115 (27.1)
Unknown 3 (1.0) 2 (0.5)
Genetic mutation 0.169
Yes 223 (71.9) 279 (65.8)
No 28 (9.0) 53 (12.5)
Not analyzed 59 (19.0) 92 (21.7)
*P value for comparison between genders by c2 test or exact Fisher test with
1 ddl for binary variables (prevalence of lesions, first lesion diagnosed), 2 or 3
ddl for categorical variables. ZES/gastrinomas, Zollinger–Ellison syndrome
and/or gastrinomas; NSPT, nonsecreting pancreatic tumors; GVS, glucago-
nomas, VIPomas, somatostatinomas.
aPercentage of patients presenting the lesion as the first one. The total
percentage exceeds 100% because two or more lesions could be
simultaneously diagnosed.was created and filled in. This CRF comprised the
following sections: identification data, pancreas gland,
parathyroid glands, pituitary gland, adrenal glands,
other endocrine tumors, thyroid, associated diseases,
genetics, and follow-up. For each lesion, the date of
occurrence, biochemical and imaging tests, medical and
surgical treatments, and pathological reports were
noted and then recorded in a computerized file. From
copies of the patients’ medical files, information was
collected on a regular basis and data were updated.
According to international recommendations, patients
should be followed-up on a regular yearly basis (2).
When data were missing or considered imprecise, an
additional query form was sent to the physician in
charge of the patient. The main centers were regularly
visited by the surgeon in charge of the database (P G).
Overall, 734 symptomatic patients (310 males and 424
females) were diagnosed between 1956 and 2005.
Of the total patients, 217 were diagnosed before 1990
(30%), 161 from 1990 to 1995 (22%), and 356 after
1995 (48%). Before 1980, 62 patients were diagnosed
(8%). The median age at the time of MEN1 diagnosis
was 39.0 years (interquartile range 28.1–47.5 years) in
males and 38.8 years (interquartile range 27.9–50.4
years) in females (PZ0.21). pHPT was present in 93%
of the patients, a duodeno-pancreatic tumor in 57%,
and a pituitary tumor in 40%. As far as the study period
of MEN1 diagnosis was concerned (!1990, 1990–
1995, R1995), there was a drop in the prevalence of
duodeno-pancreatic tumors (76%, 51%, 48%
(P!0.001)) but no change in the prevalence of either
pHPT (92%, 94%, 92% (PZ0.7)) or pituitary tumors
(43%, 44%, 36% (PZ0.1)). These periods of diagnosis
corresponded to changes in diagnostic and therapeutic
strategies (progressive use of CT, MRI, EUS, and PPI):
54% of the patients diagnosed before 1990, 81% of the
patients diagnosed during the 1990–1995 period, and
94% of those diagnosed thereafter benefited from
genetic testing (P!0.001). A total of 84% of the
patients presented either a genetic mutation and/or
were members of an MEN1 family. Follow-up data
were available for 721 patients (98.2%). The median
follow-up time after MEN1 diagnosis was 6.1 years
(interquartile range 2.3–10.3 years) in males and
6.7 years (interquartile range 2.3–10.7 years) in
females (PZ0.32), and 104 patients died (14%).Statistical analysis
Descriptive results by gender are expressed as percen-
tages for qualitative covariates, or as medians (inter-
quartile range) for quantitative variables. Pearson’s c2
test, Fischer’s exact tests, or Kruskal–Wallis tests were
used when appropriate. The following clinical lesions
were studied: parathyroid lesions, pituitary tumors,
adrenal tumors, br-NET, th-NET, ZES/gastrinomas,
insulinomas, NSPT, and a pooled group of glucagonoma,













































































































































































































































































































































4 P Goudet and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 165observation regarding the occurrence of each MEN1
lesion was calculated from the date of birth to the date of
diagnosis of the lesion, or to the last information/death.
The probability of occurrence was estimated using the
Kaplan–Meier method, and cumulative probabilities of
occurrence were calculated at 20, 40, and 60 years for
each gender. Gender differences were tested using the
log-rank test. Multivariate logistic regressions were used
to examine whether gender was an independent risk
factor for MEN1 diagnosis at the time of the first lesion,
after adjustment for age, diagnosis period, and a family
history of MEN1. This analysis was first performed in all
patients irrespective of the site of the first lesion and then
by subgroups of patients defined by the site of the first
lesion. For all analyses, a P value below 0.05 was
considered significant. Stata software, version 9.0 (Stata
Corp., College Station, TX, USA) and SAS software,
version 9.1 (SAS Institute, Inc., Cary, NC, USA), were





























































































































































































































































































































































































































































































































































































































































































































































































































































































































The majority of the patients was females (57.8%).
The main characteristics of MEN1 according to gender
are presented in Tables 1 and 2. The prevalence of
pHPT, br-NET, and adrenal tumors was similar in both
sexes. These results held true with regard to the
probability of the occurrence of adrenal tumors and
br-NET. Nevertheless, the probability of pHPT occurring
was slightly higher in men (log-rank test: PZ0.094).
Th-NET was found exclusively in men. As far as the
duodeno-pancreas was concerned, there was a signi-
ficant male predominance in terms of prevalence and
probability of ZES/gastrinomas, but there was no
gender-related difference for other duodeno-pancreatic
tumors. As described in Table 2 and illustrated in Fig. 1,
the probability of developing a ZES/gastrinomas at 60
years was 54.9% in men and only 32.5% in women.
The absolute risk for ZES/gastrinomas increases much
more in men than in women during their lifetime, with
a 7.6% difference at the age of 40 years and a 22.4%
difference at the age of 60 years. Conversely, there was a
significant female predominance for pituitary tumors
both in terms of prevalence and in terms of probability
regardless of age. A family history of MEN1 was more
frequently observed in men than in women, whereas no
significant difference was found among genders for
positive genetic testing.
Irrespective of the lesion site, the proportion of
patients diagnosed with MEN1 at the time of the first
lesion was significantly higher in men (61.0%) than in
women (53.1%) (Table 3). However, after adjustment
for age, diagnosis period, and a family history of
MEN1, female gender was only marginally associated
with a delayed diagnosis of MEN1 (female gender odds
ratio (OR): 0.77, 95% confidence interval (95% CI):
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Figure 1 Probability of gastrinoma occurrence by gender according
to age of patients.
Table 3 Proportion of patients with MEN1 diagnosis at the time of
first lesion.
Males Females
n a n (%) b n a n (%) b P *
Any lesion 310 189 (61.0) 424 225 (53.1) 0.03
As first lesion
Pancreatic tumor 121 77 (63.6) 116 71 (61.2) 0.70
Hyperparathyroidism 217 160 (73.7) 267 184 (68.9) 0.24
Pituitary tumor 55 37 (67.3) 129 57 (44.2) 0.004
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those diagnosed with MEN1 at the same time was
considerably higher in men (67.3%) than in women
(44.2%). Adjustment for age, diagnosis period, and
a family history of MEN1 did not alter this finding
(female gender OR: 0.35, 95% CI: 0.17–0.71;
PZ0.003). However, further adjustment for the
number of initial lesions reduced the gender difference
(female gender OR: 0.51, 95% CI: 0.19–1.35, PZ0.18).
Whether the multivariate analysis was performed on
the whole sample or restricted to patients with pituitary
tumors as the first lesion, age!20 years, and a family
history of MEN1 were strong predictors of an immediate
diagnosis of MEN1, whereas the period of diagnosis was
not. There were no significant gender differences
regarding the diagnosis of MEN1 in analyses restricted
to patients with pHPT, pancreatic tumors, or other
tumors as the first lesions.
For the 320 patients not diagnosed with MEN1 at the
occurrence of the first lesion, the time between the first
lesion and the diagnosis of MEN1 was slightly longer in
females (median time lag: 4.0 years, interquartile range
1.0–9.2 years) than in males (median time lag: 2.2
years, interquartile range 0.4–9.0 years) but not
significantly so (PZ0.14; Table 4). The analysis
restricted to 89 patients with pancreatic tumors as the
first lesion showed that the diagnosis of MEN1 was
significantly (PZ0.04) delayed in females (median time
lag: 3.1 years, interquartile range 1.0–6.0 years)
compared with males (median time lag: 1.3 years,
interquartile range 0.3–3.9 years). There was no
significant difference between women and men in the
delay to MEN1 diagnosis when the first lesions were
pituitary tumors, pHPT or other tumors.Other tumorsc 22 15 (68.2) 24 14 (58.3) 0.49
*P value for comparison between genders by c2 test or exact Fisher test with
1 ddl for binary variables.
a Total number of patients affected by the mentioned lesion among males and
females.
b Number and percent of patients presenting the mentioned lesion as the first
lesion and diagnosed as MEN1 at the same time among males and females.
cAdrenal tumors, thymic tumors, and bronchial tumors.Discussion
MEN1 disease is usually described as an autosomal
dominant cancer syndrome with very high penetrance,
which affects both genders equally (2, 3). For the firsttime, this present comprehensive study shows the
overall predominance of female patients in MEN1
disease and highlights the importance of gender in the
phenotype expression of various MEN1 lesions. We
demonstrated the greater lifetime likelihood of develop-
ing ZES/gastrinomas in men and of developing pituitary
tumors in women. In contrast, both genders have a
similar and very high probability of developing pHPT
whereas, as expected, th-NET occurred mostly in men
(7–10). Furthermore, the diagnosis of MEN1 tended to
be delayed in women, especially when pituitary tumors,
and to some extent duodeno-pancreatic tumors, were
the first lesions to occur in the course of the disease.
A major strength of this comprehensive clinical study
was to use well-defined diagnosis criteria in accordance
with international guidelines established after the
Gubbio meeting (1). These guidelines are used in all
French and Belgian hospital departments likely to be
involved in the management of MEN1 (1–3). Moreover,
regularly updated recommendations for screening
and diagnosis are available on the GTE website in
order to help physicians to follow the same rules in all
of the centers (http://sfendocrino.org/IMG/pdf/livret_
NEM1_2006-2.pdf). Nevertheless, despite the apparent
clarity of the diagnosis criteria, some uncertainties may
remain regarding MEN1 diagnosis in routine practice
(24, 25). Such uncertain patients were analyzed
carefully using complementary criteria before their
inclusion in the database when genetic analyses were
negative (18).
Another strength of the study is the multicenter
aspect of the data collection and the size of the cohort.
All the French regions and some Belgian regions were
involved, and our cohort was more than twice as big as
the largest previously published cohorts regularly
quoted in the literature. These large cohorts comprised
more than 200 MEN1 patients. They were located in the
USA (nZ233: 1951–1997 period of MEN1 diagnosis),
in Italy (nZ221: 1990–2003 period of MEN1 diag-
nosis), in the United Kingdom (nZ220: unknownwww.eje-online.org
Table 4 Time between the first lesion and the MEN1 diagnosis in
patients with delayed diagnosis. Values are presented as median




(95% CI) n a
Median delay
(95% CI) P *
Any lesion 121 2.2 (0.4–9.0) 199 4.0 (1.0–9.2) 0.14
As first lesion
Pancreatic tumor 44 1.3 (0.3–3.9) 45 3.1 (1.0–6.0) 0.04
Hyperparathyroidism 57 4.6 (0.5–10.3) 83 3.7 (0.4–8.8) 0.62
Pituitary tumor 18 1.7 (0.3–12.0) 72 5.2 (1.1–11.0) 0.22
Other tumorsb 7 4.6 (0.1–24.5) 10 1.5 (0.8–2.1) 0.33
95% CI, 95% confidence interval. *P value for comparison between genders
by Student’s t-test or Mann–Whitney U test.
a Total number of patients affected by a given lesion among males and
females.
bAdrenal tumors, thymic tumors, and bronchial tumors.
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1980–2006 period of MEN1 diagnosis) (9, 12, 26, 27).
The multicenter aspect of this study reduces the risk of
bias encountered in single-center cohorts, which may
select patients through a specific aspect of the disease
such as the age of the patient, or the organ involved
(duodeno-pancreas, pituitary, parathyroid glands, etc.).
Nevertheless, it is clear that this cohort was hetero-
geneous: i) the prospective method of GTE data
collection dates back to 1991, ii) the work-up and
follow-up modalities have changed over the whole study
period, iii) the rules in MEN1 patient management may
have varied from one center to another despite
recommendations, iv) CT, MRI and EUS were only
progressively available over the study period, v) and last
but not the least, patients did not always comply with
medical supervision. Moreover, and as mentioned in the
population section, the prevalence of pancreatic lesions
was greater at the beginning of the registration process.
We know that, before 1981, 80% of the MEN1 patients
were first diagnosed with the disease because of
ZES/gastrinomas since MEN1 patients were mostly
diagnosed through symptomatic presentations and
because precise guidelines had not yet been established
for the diagnosis of MEN1 (28). These first patients may
have over-expressed the importance of duodeno-
pancreatic lesions. Nevertheless, only 14% of the
patients were diagnosed with MEN1 before 1981, and
finally, no major differences in terms of prevalence were
found when the GTE results were compared with those
of the German MEN1 cohort (29): 93 vs 89% for pHPT,
57 vs 54% for duodeno-pancreatic tumors, and 40 vs
45% for pituitary tumors. These two large and
independent cohorts are very similar and are probably
representative of MEN1 disease in Western Europe
during the past 30 years.
Only scarce and somewhat discordant data are
available regarding the prevalence of MEN1 disease
and MEN1 lesions by gender. A previous study of 110www.eje-online.orgpatients dating back to 1991 reported that the
prevalence of MEN1 and the three most common
tumors (pituitary, parathyroid, and duodeno-pancreas)
in patients below 55 years was higher in women than in
men (11). The study suggested that women were
probably more likely to seek a medical consultation.
Although this interpretation was obviously not proved,
the authors considered that this gender difference was
due to a clinical bias. Recently, an overall female
predominance was also observed in four MEN1 studies
from the United States (nZ233), from the United
Kingdom (nZ220), from Germany (nZ301), and
from Finland (nZ82), showing proportions of women
of 54, 57, 59, and 57%, thus very close to our figures of
58% (12, 26, 27, 30). The 2007 study from Finland
was particularly interesting because the cohort was
constituted during a comparable period of time (1982–
2001) and was exclusively made of patients with
ascertained MEN1 mutations. Nevertheless, the aspect
of gender differences was not discussed in these
publications. In order to better understand the higher
frequency of MEN1 among females, a thorough
examination of the characteristics of the most common
lesions by gender was necessary. We found a male
predominance in the prevalence of duodeno-pancreatic
tumors mainly due to ZES-gastrinomas. It is known that
pHPT is frequently associated with ZES and that pHPT
increases basal acid secretion (31). However, pHPT is
not the explanation for this gender difference because
pHPT was found as frequently in males as in females.
A previous pooled analysis of 16 worldwide studies,
including 1009 MEN1 patients with ZES, also found
that the proportion of males was 53.8%, thus very close
to our value of 52% (16). This male predominance
should be compared with the high percentages of men
(ranging from 59.5 to 70.1%) reported in studies totally
or mostly composed of patients with sporadic ZES, i.e.
without an MEN1 background. Our study also
confirmed, as already published by the GTE group
from a previous smaller cohort, the higher prevalence of
pituitary tumors in female MEN1 patients (17). The
present analysis underscores the fact that this difference
held true for prolactinomas and for other pituitary
tumors. Like the high incidence of ZES/gastrinoma in
male patients, the high prevalence of pituitary tumors
among MEN1 women is in line with the higher female
prevalence of pituitary tumors observed in non-MEN1
patients (32, 33). A community-based study recently
conducted in the Oxford area among mostly non-MEN1
patients also found a majority of women with pituitary
tumors (66.7 vs 67.7% in the present study) (34).
Another original finding of this study is the analysis of
the gender effect on the probability of MEN1 lesions
occurring during a person’s lifetime. To our knowledge,
only one study was able to estimate the probabilities of
tumor occurrence by site, and none by gender (29). We
showed that the expression of all MEN1 lesions
progressively increases during the lifetime. When
Gender-related differences in MEN1 disease 7EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 165considering gender, the cumulative probability of a
pituitary tumor occurring was higher in women than in
men at all ages. On the contrary, the cumulative
probability of duodeno-pancreatic tumors or thymic
tumors occurring was higher in men than in women at
all ages. As reported in Fig. 1, the absolute risk for
ZES/gastrinoma increases much more in men than in
women during their lifetime. We can only hypothesize
about the underlying reasons for these gender
differences. In sporadic pituitary tumors, somatic
MEN1 gene mutations do not significantly contribute
to tumorigenesis (35, 36). In about 50% of sporadic
ZES/gastrinomas, a mutation in the MEN1 is detected
(37–39). Apparently, mutations in other genes may also
cause such tumors. In addition, gender apparently
influences the risk of tumor development in a different
way. Similar molecular events may be involved in
sporadic and familial prolactinoma and gastrinoma. If
an MEN1 mutation is present, the risk of initiating
development of these tumors is very high. In order to
explain the difference in disease expression among
MEN1 family members, one may assume that other
genes as well as gender are involved. Identification of
the underlying molecular pathway of tumorigenesis
may explain the difference in disease expression, both
between family members and between sexes. In sporadic
tumors, a different primary mutation may be respon-
sible for tumorigenesis. However, the subsequent steps,
including gender, may be similar or even identical to the
‘MEN1 pathway’ and the same cellular events may be
involved in the tumorigenesis. In this regard, it is
interesting to remember that menin, the protein
encoded by the MEN1 gene, can act as a co-activator
or co-repressor of nuclear hormone receptors including
estrogen (ERa) and androgen (AR) receptors (40). As
these receptors function as transcription factors, menin
can influence patterns of gene expression. Considering
the gender-specific differences in concentrations of the
hormones involved, and the tissue-specific distribution
of their receptors, it should at least be hypothesized that
imbalances in ERa or AR activation, as caused by a
defect in the MEN1 gene, may also be involved in
sporadic MEN1-associated tumors caused by somatic
defects in other genes. This imbalance may thus
contribute to the observed gender-specific differences in
the prevalence of pituitary tumors and gastrinoma, both
among MEN1 patients and in the general population.
An exploratory analysis also revealed for the first time
gender differences in the timing of MEN1 diagnosis. In
women, MEN1 was less frequently diagnosed at the time
of the first lesion, especially when pituitary tumor was
the first lesion (MEN1 diagnosed in 44.2% of women
versus 67.3% of men). This finding was mainly
explained by the smaller number of initial lesions in
women. The high prevalence of sporadic pituitary
adenomas in females within the general population
probably prevents clinicians from diagnosing MEN1 in
female patients. Moreover, the clinical presentation ofMEN1 revealed by a pituitary tumor is not specific in
terms of secretion and does not help physicians to
recognize MEN1 (17). Interestingly, when the first
lesions affected other organs such as the duodeno-
pancreas or parathyroid, the diagnosis of MEN1 was
established similarly in both genders. In patients for
whom an immediate diagnosis of MEN1 could not be
made on the occurrence of first lesion, no significant
difference was found between males and females in the
diagnosis time lag, possibly because of low statistical
power. Nevertheless, once again, a trend toward a
delayed diagnosis in females was found. This tendency
was significant in patients in whom the first lesion was a
duodeno-pancreatic tumor. As these exploratory find-
ings could have been due to chance, they were
interpreted with caution. A delayed diagnosis may be
due to a delay in phenotypic expression or to lesser
suspicion of the disease in women than in men. This
needs to be verified in further studies. As expected with
this genetic disease, both a young age at the time of the
first lesion and a family history were helpful in
increasing the probability of immediate MEN1 diag-
nosis. Curiously, a family history suggestive of MEN1 at
the time of the first lesion was less frequently
encountered in women than in men, while positive
genetic testing was similar in both genders. Once more,
these data suggest that MEN1 disease is less often
suspected in women, resulting in an incomplete initial
familial inquiry at the time of the first lesion.
For the first time, a comprehensive multicenter study
has shown the importance of gender in the phenotype
expression of various lesions in MEN1 disease. Possible
selection biases exist but are reduced because of the
multicenter aspect of the data collection and because of
the size of the cohort. Moreover, these results are in
agreement with data obtained in the tables available
from international publications as regards the MEN1
sex ratio, the sex ratio of pituitary tumors, and
ZES/gastrinomas in MEN1 and non-MEN1 patients.
This study also emphasizes the difficulties in routine
practice with regard to considering pituitary adenomas
as MEN1 lesions in women. In order to improve the
diagnosis of MEN1 in the future, the following advice
may be proposed: i) question patients (male or female)
presenting with a pituitary tumor, pHPT, or an
endocrine duodeno-pancreatic tumor closely about a
family history that evokes MEN1. ii) Test any patient
with a pituitary tumor or an endocrine duodeno-
pancreatic tumor for hypercalcemia to look for HPT.
iii) Carefully screen every patient presenting with a
pituitary tumor, pHPT, or endocrine duodeno-pancrea-
tic tumor occurring before 20 years of age for MEN1.
Finally, analysis of gender differences among MEN1
patients showed that phenotype expression is different
among males and females and suggests that in female
patients the possibility of MEN1 is not sufficiently taken
into account.www.eje-online.org
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